With drug-resistant bacteria on the rise, antibiotics have struggled to keep up with the challenge. Now, with the FDA’s approval of a new antibiotic for bacterial pneumonia, some of that may change. Monday, the FDA approved Nabriva Therapeutics’ Xenleta (lefamulin) to treat community-acquired
read moreDrugs from the burgeoning JAK group have run into their fair share of safety liabilities, and if the label for new AbbVie med Rinvoq is any indication, the FDA now figures those problems extend to the entire class. That doesn’t
read moreThe UK has lost its ‘measles-free’ status with WHO, just three years after the virus was eliminated in the country. More: New PM urges action to improve vaccination uptake Source: News
read moreUntil recently, Novartis CEO Vas Narasimhan seems to have navigated through several scandals unscratched. But he could have handled the Zolgensma data manipulation crisis better, he told managers during an internal call. More: Novartis CEO (sort of) admits mishandling Zolgensma
read moreAfter five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India, behind it. The FDA has indicated Sun’s improvements have reached a point where it sees no further changes from the drugmaker are
read morePfizer knew things would take a turn for the worse after generics for its blockbuster Lyrica launched stateside three short weeks ago. But did the company know it would lose this much—and so fast? More: Lyrica looking grim: Pfizer blockbuster's
read more© 1994 - 2026 B.M. Pharmaceuticals